Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
t cell exhaustion and senescence in cancer regulatory circuits and therapeutic state engineering
Original title: “T-Cell Exhaustion and Senescence in Cancer: Regulatory Circuits and Therapeutic State Engineering.”
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to MedGene Therapeutics, Inc. ("MedGene"), a company located in Silver Spring, Maryland, the United States of America.
Original title: “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers”
Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to break through where others have previously failed.
Original title: “5 drugmakers chasing Merck and Moderna in the cancer vaccine race”
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
Original title: “mRNA cancer vaccines’ biggest barriers to market”
canvar uk a collaborative platform for germline interpretation in cancer susceptibility genes
Original title: “CanVar-UK: A collaborative platform for germline interpretation in cancer susceptibility genes.”
cancer driver agnostic targeting of amplified surface proteins identifies mpzl1 for selective car t cell therapy
Original title: “Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy.”
Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
Original title: “A new immuno-oncology play raises $225M for a next-generation drug”
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
Original title: “GSK wagers up to $1.3B on a different kind of cancer drug”
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
Original title: “Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines”
Through its DualityBio deal, Roche's Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.
Original title: “Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio”
autoimmune disease patients with comorbid cancer exhibit prominent immunometabolic crosstalk
Original title: “Autoimmune disease patients with comorbid cancer exhibit prominent immunometabolic crosstalk.”
Study shows reversible switch for targeted cytokine delivery
Original title: “FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough”
corrigendum to csde1 enhances genotoxic drug resistance in cancer by modulating rpa2 through the csde1 eif3a regulatory complex drug resist updat 81 2025 101249
Original title: “Corrigendum to "CSDE1 enhances genotoxic drug resistance in cancer by modulating RPA2 through the CSDE1-eIF3a regulatory complex" [Drug Resist. Updat. 81 (2025) 101249].”
Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
Original title: “Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future”
epigenetic reprogramming of lineage switching in cancer
Original title: “Epigenetic reprogramming of lineage switching in cancer.”
beyond morphology reframing lymph node metastasis prediction through clonal ecology decades long genomic instability and polyclonal to monoclonal transitions as the missing dimension in cancer
Original title: “Beyond Morphology: Reframing Lymph-Node Metastasis Prediction Through Clonal Ecology-Decades-Long Genomic Instability and Polyclonal-to-Monoclonal Transitions as the Missing Dimension in Cancer.”
Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.
Original title: “Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition”
patients with cardiac implantable electronic devices undergoing radiation therapy for cancer or magnetic resonance imaging
Original title: “Patients with cardiac implantable electronic devices undergoing radiation therapy for cancer or magnetic resonance imaging.”
This technology encompasses a DNA methylation-based diagnostic platform designed to improve the accuracy and consistency of cancer classification, with demonstrated utility for tumors of the central nervous system, kidney, and hematopoietic system. By identifying disease-specific methylation signatures, the approach reduces interobserver variability and enhances diagnostic confidence. The central nervous system (CNS) classifier is built from a curated reference set of 16,567 methylation profiles
Original title: “Government Owned Invention Available for License: DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification”
Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL- 12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.
Original title: “NIH Owned Invention Available for License: Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy”